ArticleMovement disorders : official journal of the Movement Disorder Society2026
Missense Variants in the A Isoform of FGF13 as a Novel Cause of Paroxysmal Dyskinesia.
Article in Movement disorders : official journal of the Movement Disorder Society, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
23 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPathogenic variants within the unique N-terminal inactivation particle of FGF13 isoform A (FGF13A) have so far been associated only with an X-linked dominant epileptic encephalopathy (DEE).
objectiveThe aim was to expand the clinical and molecular spectrum of FGF13A-related disorder.
methodsWe performed exome or genome sequencing of patients with unexplained nonepileptic paroxysmal dyskinesia (PxD).
resultsFour unrelated boys with three novel de novo or inherited pathogenic missense variants in FGF13A were identified. Variants were also located within the inactivation particle, proximal to the DEE variants. Carrier mothers were unaffected, indicating an X-linked recessive inheritance. All patients presented with PxD in infancy, consisting of both hyperkinetic and hypokinetic-hypotonic phases, and a variable neurodevelopmental disorder. The frequency of attacks was high (60-100 per day). Treatment with caffeine with or without methylphenidate partially improved PxD in 2 patients.
conclusionsFGF13A variants cause a partially caffeine-responsive PxD phenotype with variable cognitive impairment, albeit without epilepsy. © 2026 The Author(s). Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.